We further provide evidence that pharmacological and genetic ablation of these molecules in mice reverses the adverse renal effects of obesity; therefore, an intervention targeting the HA-CD44/RHAMM pathway may represent a novel therapeutic strategy against the progression of obesity-induced kidney injury. Here, CD44 is linked to Obesity.